Interim 1-year data, phase 1b/2 trial in 63 adults and 111 children in Tanzania: single-dose ChAdOx2 RabG caused mostly mild-to-moderate reactions and no serious adverse reactions; day-365 antibody titres (secondary outcome) exceeded single-visit IRV vaccine.
RCTn = 174
Ritchie et al. Safety and immunogenicity of a single-dose adenovirus-vectored rabies vaccine over 1 year in adults and children in Tanzania: interim data from an ongoing, partly randomised, controlled, phase 1b/2 trial